Ann: Presentation to Investors, page-3

If someone read the Annual report -

Commercialisation
The Company’s preclinical and clinical development
activities are undertaken with the sole aim of achieving
a commercial outcome for its promising antiviral
programs.
The COVID-19 pandemic and other infectious disease
outbreaks in recent years highlight the importance
of novel approaches such as Biotron’s viroporin
compounds which have the potential to target a broad
range of existing and emerging viruses. Therapeutic
drugs such as those in development by Biotron are vital
in the fight against pandemics.
Licensing or sale of innovative technology and products
by biotechnology companies such as Biotron to major
pharmaceutical company partners first requires
demonstration of clinical efficacy. The Company has
been sharing information on its antiviral programs with
potential partners in the pharmaceutical industry since
early preclinical development.
Discussions with pharmaceutical companies are
iterative in nature. Every successful series of
experiments or clinical trial generates another series
of questions that will guide the decision-making
process on the side of commercial partners. Good,
well-founded science is core to success. Feedback from
potential partners, as well as advice from experienced
international clinical, regulatory and industry advisors
has informed every step of development activities
undertaken by the Company.